Literature DB >> 17160618

Extracellular matrix turnover and disease severity in Anderson-Fabry disease.

J S Shah1, D A Hughes, M H Tayebjee, R J MacFadyen, A B Mehta, P M Elliott.   

Abstract

BACKGROUND: Anderson-Fabry Disease (AFD) is an inherited metabolic disease associated with premature death secondary to cardiovascular and renal disease. Patients with AFD develop progressive left ventricular (LV) remodelling and heart failure. We hypothesized that altered extracellular matrix (ECM) turnover contributes to the pathophysiology of cardiac disease in AFD. METHODS AND
RESULTS: Twenty-nine consecutive patients (44.1 +/- 11.7 years, 15 male) with AFD and 21 normal controls (39.7 +/- 11.3 years, 10 male) had serum analysed for matrix metalloproteinase-9 (MMP-9), and tissue inhibitor of matrix metalloproteinase-1 and -2 (TIMP-1, TIMP-2). All patients underwent clinical assessment, echocardiography and Mainz Severity Score Index (MSSI) measurement, a validated severity score in AFD. MMP-9 levels were significantly higher in patients than controls (1003.8 +/- 337.8 ng/ml vs 576.7 +/- 276.3 ng/ml respectively, p < 0.001). There were no differences in TIMP levels between patients and controls. There was a positive correlation between MMP-9 levels and MSSI (r = 0.5, p = 0.01). There was a negative correlation between MMP-9 and endocardial fractional shortening (FS) (r = -0.5, p = 0.01) and mid-wall FS (r = -0.6, p = 0.001). There was no correlation between other echocardiographic parameters and MMP-9 levels. These relations were independent of age and sex using stepwise linear regression analysis.
CONCLUSIONS: Patients with AFD have abnormal ECM turnover compared to normal controls. The correlation between MMP-9 levels and systolic function suggests that altered ECM turnover is important in cardiac remodelling. The association between MMP-9 and overall disease severity suggests that circulating levels of MMP-9 may provide a useful marker for assessing the response of patients with AFD to enzyme replacement treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17160618     DOI: 10.1007/s10545-006-0360-6

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  33 in total

Review 1.  Matrix metalloproteinases in coronary artery disease: clinical and therapeutic implications and pathological significance.

Authors:  Muzahir H Tayebjee; Gregory Y H Lip; Robert J MacFadyen
Journal:  Curr Med Chem       Date:  2005       Impact factor: 4.530

2.  Relation of left ventricular midwall function to cardiovascular risk factors and arterial structure and function.

Authors:  R B Devereux; G de Simone; T G Pickering; J E Schwartz; M J Roman
Journal:  Hypertension       Date:  1998-04       Impact factor: 10.190

3.  Matrix metalloproteinases: biologic activity and clinical implications.

Authors:  A R Nelson; B Fingleton; M L Rothenberg; L M Matrisian
Journal:  J Clin Oncol       Date:  2000-03       Impact factor: 44.544

4.  Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome.

Authors:  Y Inokubo; H Hanada; H Ishizaka; T Fukushi; T Kamada; K Okumura
Journal:  Am Heart J       Date:  2001-02       Impact factor: 4.749

5.  Arterial remodelling in Fabry disease.

Authors:  P Boutouyrie; S Laurent; B Laloux; O Lidove; J P Grunfeld; D P Germain
Journal:  Acta Paediatr Suppl       Date:  2002

6.  Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: the Framingham Heart Study.

Authors:  Johan Sundström; Jane C Evans; Emelia J Benjamin; Daniel Levy; Martin G Larson; Douglas B Sawyer; Deborah A Siwik; Wilson S Colucci; Patrice Sutherland; Peter W F Wilson; Ramachandran S Vasan
Journal:  Circulation       Date:  2004-06-01       Impact factor: 29.690

7.  Tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9 levels in patients with hypertension Relationship to tissue Doppler indices of diastolic relaxation.

Authors:  Muzahir H Tayebjee; Sunil K Nadar; Robert J MacFadyen; Gregory Y H Lip
Journal:  Am J Hypertens       Date:  2004-09       Impact factor: 2.689

8.  Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey.

Authors:  A Mehta; R Ricci; U Widmer; F Dehout; A Garcia de Lorenzo; C Kampmann; A Linhart; G Sunder-Plassmann; M Ries; M Beck
Journal:  Eur J Clin Invest       Date:  2004-03       Impact factor: 4.686

9.  TIMP-1: a marker of left ventricular diastolic dysfunction and fibrosis in hypertension.

Authors:  M Mitchell Lindsay; Paul Maxwell; Francis G Dunn
Journal:  Hypertension       Date:  2002-08       Impact factor: 10.190

10.  Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium.

Authors:  James C C Moon; Bhavesh Sachdev; Andrew G Elkington; William J McKenna; Atul Mehta; Dudley J Pennell; Philip J Leed; Perry M Elliott
Journal:  Eur Heart J       Date:  2003-12       Impact factor: 29.983

View more
  7 in total

1.  Elevated circulating levels of matrix metalloproteinases MMP-2 and MMP-9 in pseudoxanthoma elasticum patients.

Authors:  Ulf Diekmann; Ralf Zarbock; Doris Hendig; Christiane Szliska; Knut Kleesiek; Christian Götting
Journal:  J Mol Med (Berl)       Date:  2009-07-03       Impact factor: 4.599

2.  Agalsidase alfa (Replagal) in the treatment of Anderson-Fabry disease.

Authors:  Gregory M Pastores
Journal:  Biologics       Date:  2007-09

Review 3.  Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibodies.

Authors:  Johannes M F G Aerts; Wouter W Kallemeijn; Wouter Wegdam; Maria Joao Ferraz; Marielle J van Breemen; Nick Dekker; Gertjan Kramer; Ben J Poorthuis; Johanna E M Groener; Josanne Cox-Brinkman; Saskia M Rombach; Carla E M Hollak; Gabor E Linthorst; Martin D Witte; Henrik Gold; Gijs A van der Marel; Herman S Overkleeft; Rolf G Boot
Journal:  J Inherit Metab Dis       Date:  2011-03-29       Impact factor: 4.982

Review 4.  Biomarkers and Imaging Findings of Anderson-Fabry Disease-What We Know Now.

Authors:  Idalina Beirão; Ana Cabrita; Márcia Torres; Fernando Silva; Patrício Aguiar; Francisco Laranjeira; Ana Marta Gomes
Journal:  Diseases       Date:  2017-06-11

5.  Biomarkers of Myocardial Fibrosis: Revealing the Natural History of Fibrogenesis in Fabry Disease Cardiomyopathy.

Authors:  Patrício Aguiar; Olga Azevedo; Rui Pinto; Jacira Marino; Carlos Cardoso; Nuno Sousa; Damião Cunha; Derralynn Hughes; José Luís Ducla Soares
Journal:  J Am Heart Assoc       Date:  2018-03-13       Impact factor: 5.501

6.  Serum Biomarkers of Endothelial Dysfunction in Fabry Associated Cardiomyopathy.

Authors:  Jefferson Loso; Natalie Lund; Maxim Avanesov; Nicole Muschol; Susanne Lezius; Kathrin Cordts; Edzard Schwedhelm; Monica Patten
Journal:  Front Cardiovasc Med       Date:  2018-08-15

7.  Elevated Inflammatory Plasma Biomarkers in Patients With Fabry Disease: A Critical Link to Heart Failure With Preserved Ejection Fraction.

Authors:  Haran Yogasundaram; Anish Nikhanj; Brendan N Putko; Michel Boutin; Shailly Jain-Ghai; Aneal Khan; Christiane Auray-Blais; Michael L West; Gavin Y Oudit
Journal:  J Am Heart Assoc       Date:  2018-11-06       Impact factor: 5.501

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.